Use of immunobiological drugs in the treatment of rheumatoid arthritis
https://doi.org/10.29235/1814-6023-2018-15-4-493-502
Abstract
In this article, we discuss the modern approaches to optimize rheumatoid arthritis therapy with biological antiinflammatory drugs using specific predictors. We describe the most important predictors such as body mass index, smoking, disease activity, concomitant therapy, and the presence of antibodies in predicting the effectiveness of biologicals. Also, we provide data on the ability to predict the response to a certain type of biological therapy on the basis of clinical variants of rheumatoid arthritis.
About the Authors
M. V. Volkava
Belarusian Medical Academy of Postgraduate Education, Minsk
Belarus
Ph. D. (Med.), Leading researcher
Belarus
Ph. D. (Med.), Leading researcher
A. V. Kunder
Belarusian Medical Academy of Postgraduate Education, Minsk
Belarus
D. Sc. (Med.), Professor
Belarus
D. Sc. (Med.), Professor
References
1. Smolen J. S., Breedveld F. C., Burmester G. R., Bykerk V., Dougados M., Emery P. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 2016, vol. 75, no. 1, pp. 3–15. https://doi.org/10.1136/annrheumdis-2015-207524
2. Kiely P. D. W. Biologic efficacy optimization – a step towards personalized medicine. Rheumatology, 2015, vol. 55, no. 5, pp. 780–788. https://doi.org/10.1093/rheumatology/kev356
3. Joensuu J. T., Huoponen S., Aaltonen K. J., Konttinen Y. T., Nordström D., Blom M. The cost-effectiveness of bio logics for the treatment of rheumatoid arthritis: a systematic review. PLoS ONE, 2015, vol. 10, no. 3, pp. e0119683. https://doi.org/10.1371/journal.pone.0119683
4. Firestein G. S. The disease formerly known as rheumatoid arthritis. Arthritis Research & Therapy, 2014, vol. 16, no. 3, art. 114. https://doi.org/10.1186/ar4593
5. Kunder E. V., Volkova M. V., Buglova A. E., Rudenko E. V., Maslinskaya L. N., Petrovich D. M. et al. Clinical polymorphism of rheumatoid arthritis in the Belarusian patient population. Meditsina [Medicine], 2017, no. 2, pp. 63–70 (in Russian).
6. Gibson D. S., Bustard M. J., McGeough C. M., Murray H. A., Crockard M. A., McDowell A., Blayney J. K., Gardiner P. V., Bjourson A. J. Current and future trends in biomarker discovery and development of companion diagnostics for arthritis. Expert Review of Molecular Diagnostics, 2014, vol. 15, no. 2, pp. 219–234. https://doi.org/10.1586/14737159.2015.969244
7. Plant D., Wilson A. G., Barton A. Genetic and epigenetic predictors of responsiveness to treatment in RA. Nature Reviews Rheumatology, 2014, vol. 10, no. 6, pp. 329–337. https://doi.org/10.1038/nrrheum.2014.16
8. Dennis Jr. G., Holweg C. T., Kummerfeld S. K., Choy D. F., Setiadi A., Hackney J. A. et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Research and Therapy, 2014, vol. 16, no. 2, pp. R90. https://doi.org/10.1186/ar4555
9. Townsend M. J. Molecular and cellular heterogeneity in the Rheumatoid Arthritis synovium: clinical correlates of synovitis. Best Practice and Research Clinical Rheumatology, 2014, vol. 28, no. 4, pp. 539–549. https://doi.org/10.1016/j.berh.2014.10.024
10. Hyrich K. L., Watson K. D., Silman A. J., Symmons D. P. M. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2006, vol. 45, no. 12, pp. 1558–1565. https://doi.org/10.1093/rheumatology/kel149
11. Nam J. L., Winthrop K. L., van Vollenhoven R. F, Pavelka K., Valesini G., Hensor E. M. A. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Annals of the Rheumatic Diseases, 2010, vol. 69, no. 6, pp. 976–986. https://doi.org/10.1136/ard.2009.126573
12. Daïen C. I., Morel J. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. Mediators of Inflammation, 2014, vol. 2014, art. ID 386148. https://doi.org/10.1155/2014/386148
13. Goodman S. M., Ma Y., Zhang W., Schulman E., Bartlett S. J., Andersen K. M. et al. Body mass index is an independent risk factor for not achieving sustained remission in early rheumatoid arthritis: results from the CATCH observational study. Annals of the Rheumatic Diseases, 2015, vol. 74, suppl. 2, pp. 138.2–139. https://doi.org/10.1136/annrheumdis-2015-eular.1973
14. Gremese E., Carletto A., Padovan M., Atzeni F., Raffeiner B., Giardina A. R. et al. Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care and Research, 2012, vol. 65, no. 1, pp. 94–100. https://doi.org/10.1002/acr.21768
15. Saevarsdottir S., Wedrén S., Seddighzadeh M., Bengtsson C., Wesley A., Lindblad S., Askling J., Alfredsson L., Klareskog L. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis and Rheumatism, 2010, vol. 63, no. 1, pp. 26–36. https://doi.org/10.1002/art.27758
16. Kristensen L. E., Kapetanovic M. C., Gülfe A., Soderlin M., Saxne T., Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology, 2007, vol. 47, no. 4, pp. 495–499. https://doi.org/10.1093/rheumatology/ken002
17. Soliman M. M., Hyrich K. L., Lunt M., Watson K. D., Symmons D. P. M., Ashcroft D. M. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British society for rheumatology biologics register. Journal of Rheumatology, 2011, vol. 39, no. 2, pp. 240–246. https://doi.org/10.3899/jrheum.110610
18. Van Schouwenburg P. A., Rispens T., Wolbink G. J. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nature Reviews Rheumatology, 2013, vol. 9, no. 3, pp. 164–172. https://doi.org/10.1038/nrrheum.2013.4
19. Kunder E. V. Immunogenicity of tumor necrosis factor-alpha blockers as a cause of resistance to therapy. Lechebnoe delo [Therapeutics], 2017, no. 2, pp. 55–64 (in Russian).
20. Isaacs J. D., Cohen S. B., Emery P., Tak P., Wang J., Lei G., Williams S., Lal P., Read S. J. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Annals of the Rheumatic Diseases, 2012, vol. 72, no. 3, pp. 329–336. https://doi.org/10.1136/annrheumdis-2011-201117
21. Lal P., Su Z., Holweg C. T., Silverman G. J., Schwartzman S., Kelman A., Read S., Spaniolo G., Monroe J. G., Behrens T. W., Townsend M. J. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment Arthritis and Rheumatism, 2011, vol. 63, no. 12, pp. 3681–3691. https://doi.org/ 10.1002/art.30596
22. Feist E., Dörner T. Personalized medicine for rheumatoid arthritis:serological and clinical patients profiles to optimize B and T cell targeted therapy. Zeitschrift für Rheumatologie, 2013, vol. 72, no. 1, pp. 49–58. https://doi.org/ 10.1007/s00393-011-0885-4
23. Sellam J., Riviere E., Courties A., Rouzarie P.-O., Tolusso B., Vital E. M., Emery P., Ferraccioli G., Soubrier M., Ly B., Chavez H. H., Taoufic Y., Dougados M., Mariette X. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Research and Therapy, 2016, vol. 18, no. 1, р. 294. https://doi.org/ 10.1186 / s13075-016-1190-z
24. Lv Q., Yin Y., Li X., Shan G., Wu X., Liang D., Li Y., Zhang X. The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFa agent treatment in patients with rheumatoid arthritis: a metaanalysis. PLoS ONE, 2014, vol. 9, no. 2, p. e89442. https://doi.org/10.1371/journal.pone.0089442
25. Porter D., van Melckebeke J., Dale J., Messow C. M., McConnachie A., Walker A. et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet, 2016, vol. 388, no. 10041, pp. 239–247. https://doi.org/10.1016/s0140-6736(16)00380-9
26. Singh J. A., Beg S., Lopez-Olivo M. A. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. Journal of Rheumatology, 2011, vol. 38, no. 1, pp. 10–20. https://doi.org/10.3899/jrheum.100717
27. Alfonso-Cristancho R., Armstrong N., Arjunji R., Riemsma R., Worthy G., Ganguly R., Kleijnen J. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis. Clinical Rheumatology, 2016, vol. 36, no. 1, pp. 25–34. https://doi.org/10.1007/s10067-016-3435-2
28. Gabay C., Emery P., van Vollenhoven R., Dikranian A., Alten R., Pavelka K. et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet, 2013, vol. 381, no. 9877, pp. 1541–1550. https://doi.org/10.1016/s0140-6736(13)60250-0
29. Alam J., Jantan I., Bukhari S. N. A. Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharma cotherapy. Biomedicine and Pharmacotherapy, 2017, vol. 92, pp. 615–633. https://doi.org/10.1016/j.biopha.2017.05.055
30. Nishimoto N., Kishimoto T. Interleukin 6: from bench to bedside. Nature Clinical Practice Rheumatology, 2006, vol. 2, no. 11, pp. 619–626. https://doi.org/10.1038/ncprheum0338
31. Paul S. K., Montvida O., Best J. H., Gale S., Pethoe-Schramm A., Sarsour K. Effectiveness of biologic and non biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: new evidence from real-world data. Seminars in Arthritis and Rheumatism, 2018, vol. 47, no. 4, pp. 478–484. https://doi.org/10.1016/j.semarthrit.2017.08.001
32. Pandian V. P., Srinivasan R. Ocular manifestations of rheumatoid arthritis and their correlation with anti-cyclic citrullinated peptide antibodies. Clinical Ophthalmology, 2015, vol. 9, pp. 393–397. https://doi.org/10.2147/opth.s77210
33. Assmann G., Pfreundschuh M., Voswinkel J. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers. Clinical and Experimental Rheumatology, 2010, vol. 28, no. 1, suppl. 57, pp. 81–83.
34. Chandra P. A., Margulis Y., Schiff C. Rituximab is useful in the treatment of Felty’s syndrome. American Journal of Therapeutics, 2008, vol. 15, no. 4, pp. 321–322. https://doi.org/10.1097/mjt.0b013e318164bf32
35. Iaccheri B., Androudi S., Bocci E. B., Gerli R., Cagini C., Fiore T. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocular Immunology and Inflammation, 2010, vol. 18, no. 3, pp. 223–225. https://doi.org/10.3109/09273941003739928
36. Barczyńska T. A., Węgierska M., Żuchowski P., Dura M., Zalewska J., Waszczak M., Jeka S. Coexistence of rheumatoid arthritis and ankylosing spondylitis. Reumatologia, 2015, vol. 5, pp. 279–285. https://doi.org/10.5114/reum.2015.55832
37. Mazzucchelli R., Yebra M., Barbadillo C., Berrocal E., Gea J. C., Andreu-Sanchez J. L. Double disease in rheumatology: coexistence of rheumatoid arthritis and psoriatic arthritis. Clinical and Experimental Rheumatology, 1992, vol. 10, no. 1, pp. 83–85.
38. Toussirot E., Wendling D. Crohn’s disease associated with seropositive rheumatoid arthritis. Clinical and Experimental Rheumatology, 1997, vol. 15, no. 3, pp. 307–311.
39. Bogas M., Afonso M. C., Araújo D. Erosive enteropathy in a patient with polyarthritis. Acta Reumatologica Portuguesa, 2006, vol. 31, no. 4, pp. 349–354.
40. Cruz V. A., Yamaguchi L., Ribeiro C. N., Magalhães Vde O., Rego J., Silva N. A. Ulcerative colitis and rheumatoid arthritis: a rare association – case report. Revista Brasileira de Reumatologia, 2012, vol. 52, no. 4, pp. 648–650.
41. Azevedo V. F., Buiar P. G. Concurrent rheumatoid arthritis and ankylosing spondylitis in one patient: the importance of new classification criteria. Revista Brasileira de Reumatologia (English Edition), 2013, vol. 53, no. 1, pp. 111–119. https://doi.org/10.1016/s2255-5021(13)70011-7
42. El-Gabalawy H. S., Goldbabach-Mansky R., Smith D., Arayssi T., Bale S., Gulko P. et al. Association of HLA alleles and clinical features in patients with synovitis of recent onset. Arthritis and Rheumatism, 1999, 42, no. 8, pp. 1696–1705. https://doi.org/10.1002/1529-0131(199908)42:83.0.co;2-k
43. Jajić Z., Jajić I. HLA B27 antigen and rheumatoid arthritis. Acta Medica Iugoslavica, 1991, vol. 45, no. 3, pp. 195–202. 44. Mera-Varela A., Ferreiro-Iglesias A., Perez-Pampin E., Porto-Silva M., Gómez-Reino J. J., Gonzalez A. Ultrasonographic assessment of enthesitis in HLA-B27 positive patients with rheumatoid arthritis, a matched case-only study. PLoS ONE, 2013, vol. 8, no. 3, p. e58616. https://doi.org/10.1371/journal.pone.0058616
44. Saraux A., Guedes C., Allain J., Vails I., Baron D., Youinou P., Le Goff P. HLA-B27 in French patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 1997, vol. 26, no. 4, pp. 269–271. https://doi.org/10.3109/03009749709105315
45. Jurik A. G., de Carvalho A., Graudal H. Radiographic visualisation of seropositive rheumatoid arthritis in carriers of HLA-B27. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 1987, vol. 147, no. 7, pp. 14–20. https://doi.org/10.1055/s-2008-1048582
Review
For citations:
Volkava M.V., Kunder A.V. Use of immunobiological drugs in the treatment of rheumatoid arthritis. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2018;15(4):493-502. (In Russ.) https://doi.org/10.29235/1814-6023-2018-15-4-493-502
Views: 834
Email this article 